Kelly L. Lancaster - Concepedia

Author

Kelly L. Lancaster

Also Known As

Kelly L. Lancaster, Kelly Lancaster

Publications

154

Citations

H-Index

Concepts

All Affiliations

Kelly L. Lancaster is an author at Mersana Therapeutics (United States) specializing in tumor biology, tumor immunology, and tumor immunity.

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	24
2	Immunology	1	1	24
3	Pharmacology	1	1	24
4	Immune Surveillance	1	1	24
5	Immunotherapy	1	1	24

Kelly L. Lancaster

Publications

143

Citations

H-Index

Page 1

	Year	Citations
Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses Naniye Malli Cetinbas, Travis Monnell, Jahna Soomer-James, Nature Communications	2024	55
Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates Jeremy R. Duvall, Joshua D. Thomas, Raghida A. Bukhalid, Journal of Medicinal Chemistry	2023	44
Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab Jeremy R. Duvall, Raghida A. Bukhalid, Naniye Mallı Cetinbas, Cancer Research ImmunologyImmunoeditingNovel EpitopeImmunotherapeuticsSting Agonist	2022	24
XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells Raghida A. Bukhalid, Jeremy R. Duvall, Kelly L. Lancaster, Clinical Cancer Research	2025	20

Page 1